•SEP-631 demonstrated robust, dose-dependent inhibition of skin wheal formation, with complete inhibition observed at doses as low as 10 mg once-daily.
•The drug was well-tolerated across all doses studied with an adverse event profile comparable to placebo.
•Phase 2 development for Chronic Spontaneous Urticaria (CSU) is planned to begin in the second half of 2026.